IXICO PLC — AGM Information 2021

Jan 21, 2021

National Storage Mechanism | Additional information

RNS Number : 4748M

IXICO plc

21 January 2021

IXICO plc

("IXICO" or the "Company")

Results of AGM

IXICO plc (AIM: IXI), the AI digital technologies company serving neuroscience, announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:

Resolution	Description	Total Votes For	% Votes	Total Votes Against	Withheld
1	Reports and Accounts	30,185,052	99.95%	15,600	400
2	Re-election of Directors
Re-election of Mark Warne	30,185,152	99.95%	15,900	0
Re-election of John Bradshaw	30,185,452	99.95%	15,600	0
3	Re-appointment of Auditors	30,065,960	99.57%	128,100	6,992
4	Allotment of Securities	30,180,960	99.94%	17,100	2,992
5	Disapply Pre-Emption Provisions	30,180,010	99.94%	18,050	2,992
6	Amendment of rule 3.6.1 of the Company's 2014 EMI Share Option Plan	30,165,610	99.89%	33,350	1,992

For further information please contact:

IXICO plc			+44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)				+44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)
Walbrook PR Ltd	+44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne /		IXICO@walbrookpr.com
Alice Woodings

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IxicOplc 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGDKDBPKBKDFDB